~$9–11B
Pharmaceutical market value 2026
~85M
Population
~55%
Local production share (volume)
12–18 mo
TİTCK registration timeline
Turkey Pharmaceutical Market Overview
Turkey is one of the world's top-20 pharmaceutical markets, valued at approximately US$9–11 billion in 2026, with a population of ~85 million and universal health coverage through SGK (Social Security Institution). The market combines a strong domestic manufacturing base — over 100 plants, several EU-GMP certified — with full multinational presence.
TİTCK (Türkiye İlaç ve Tıbbi Cihaz Kurumu) regulates registration, pricing, and pharmacovigilance. Pricing follows external reference pricing against the cheapest EU basket with a government-set fixed exchange rate, which compresses euro-denominated revenue and shapes launch sequencing decisions.
The government's localization policy incentivises technology transfer and local production for SGK reimbursement listing, driving joint ventures between MNCs and local manufacturers such as Abdi İbrahim, Bilim, and Deva.
Top Pharmaceutical Companies in Turkey
The following table lists the major pharmaceutical companies operating in Turkey — including local manufacturers, multinational offices, regional players, and leading distributors.
| Company | HQ |
|---|---|
| Abdi İbrahim | Turkey |
| Bilim Pharmaceuticals | Turkey |
| Deva Holding | Turkey |
| Sanovel | Turkey |
| Nobel İlaç | Turkey |
| World Medicine | Turkey |
| Koçak Farma | Turkey |
| Pfizer | USA |
| Novartis | Switzerland |
| Roche | Switzerland |
| Sanofi | France |
| AstraZeneca | UK / Sweden |
| GSK | UK |
| MSD | USA |
| Novo Nordisk | Denmark |
| Bayer | Germany |
| Amgen (Gensenta) | USA / Turkey |
| Hikma Pharmaceuticals | Jordan / UK |
| Selçuk Ecza Deposu | Turkey |
| Alliance Healthcare Turkey (Hedef) | Turkey |
Planning research in Turkey?
Primary research, market access & HEOR. Proposals within 48 hours.
BioNixus market research
Commission custom Turkey fieldwork
Book a 30-minute briefing to align on TİTCK pathway intelligence, stakeholder mapping, and competitive tracking for Turkey.
List of Pharmaceutical Companies in Turkey by Category
Turkey pharmaceutical companies span local manufacturers, multinational corporation offices, regional suppliers, and key distributors.
Local Manufacturers
Turkey has one of the strongest local manufacturing bases in the region — Abdi İbrahim, Bilim, Deva, Sanovel, Nobel, World Medicine, and Koçak Farma produce generics, branded generics, and increasingly biosimilars, with EU-GMP export capability.
- ✓ Abdi İbrahim
- ✓ Bilim Pharmaceuticals
- ✓ Deva Holding
- ✓ Sanovel
- ✓ Nobel İlaç
- ✓ World Medicine
- ✓ Koçak Farma
Multinational Offices
All major multinational pharmaceutical companies operate Turkish affiliates. Localization policy pushes MNCs toward local manufacturing partnerships or technology transfer for SGK reimbursement advantage.
- ✓ Pfizer
- ✓ Novartis
- ✓ Roche
- ✓ Sanofi
- ✓ AstraZeneca
- ✓ GSK
- ✓ MSD
- ✓ Novo Nordisk
- ✓ Bayer
- ✓ Amgen (Gensenta)
Regional Players
Regional MENA players such as Hikma supply injectables and specialty generics into the Turkish hospital channel.
- ✓ Hikma Pharmaceuticals
Distributors
Distribution is consolidated: Selçuk Ecza and Alliance Healthcare (Hedef) together serve most of Turkey's ~28,000 retail pharmacies.
- ✓ Selçuk Ecza Deposu
- ✓ Alliance Healthcare Turkey (Hedef)
Pharmaceutical Companies in Turkey: TİTCK Regulatory Landscape
Turkish Medicines and Medical Devices Agency is Turkey's pharmaceutical regulator.
Regulatory Authority
Turkish Medicines and Medical Devices Agency (TİTCK) oversees registration, quality control, pricing, vigilance, and import licensing.
Registration Timeline
12–18 months
Renewal Period
5 years
Pricing Model
External reference pricing (cheapest EU basket, fixed EUR/TRY conversion rate)
Key Registration Requirements
- ✓CTD dossier in Turkish/English via TİTCK e-submission
- ✓GMP inspection or recognised certificate (TİTCK conducts own inspections)
- ✓Turkish labelling and package leaflet
- ✓Local authorised representative / marketing authorisation holder
- ✓SGK reimbursement application separate from registration
- ✓Localization commitments favour reimbursement listing
Market Access Note
SGK (Social Security Institution) reimbursement is the commercial gatekeeper — over 90% of pharmaceutical volume flows through SGK-reimbursed channels. The annually negotiated fixed exchange rate for reference pricing is the single biggest commercial variable for imported products.
Turkey Pharmaceutical Market Growth Drivers
Universal Coverage via SGK
Near-universal SGK coverage sustains high pharmaceutical volume across a population of 85 million with rising chronic disease prevalence.
Localization & Biosimilar Policy
Government localization incentives and biosimilar substitution targets drive technology transfer and local plant investment.
Export Hub Position
EU-GMP certified plants make Turkey a manufacturing and export hub for MENA, CIS, and increasingly EU markets.
Health Tourism & City Hospitals
The PPP city-hospital programme added significant tertiary capacity, expanding hospital pharmaceutical and device demand.
Oncology & Specialty Growth
Oncology, immunology, and rare disease spending is growing fastest as TİTCK accelerates innovative approvals.
Pricing Reform Watch
Periodic adjustments to the reference-pricing exchange rate create step-change revenue events that reward close market monitoring.
How BioNixus Supports Pharmaceutical Companies in Turkey
BioNixus is a healthcare market research company with primary-research capability in Turkey and cross-market benchmarking against GCC, USA, and European markets. We help pharma, biotech, and medtech companies with:
Physician Surveys & KOL Mapping
Quantitative and qualitative research with Turkish physicians across university, city-hospital, and private channels — Turkish-language fieldwork.
Market Access & TİTCK Strategy
TİTCK registration pathway analysis, SGK reimbursement and pricing intelligence, and localization partner assessment.
Competitive Intelligence
Tracking competitor launches, SGK listing decisions, tender outcomes, and local manufacturer pipelines.
Turkey vs GCC Benchmarking
Comparative market entry analysis for companies sequencing Turkey against Gulf, European, and MENA launches.
Frequently Asked Questions
How many pharmaceutical companies operate in Turkey?
Turkey has over 100 pharmaceutical manufacturing facilities and roughly 300 registered pharmaceutical companies. The top 20 include local leaders Abdi İbrahim, Bilim, Deva, Sanovel, Nobel and multinationals Pfizer, Novartis, Roche, Sanofi, AstraZeneca, GSK, MSD, Novo Nordisk, Bayer and Amgen (Gensenta), plus dominant wholesalers Selçuk Ecza and Alliance Healthcare.
What is the size of Turkey's pharmaceutical market?
Turkey's pharmaceutical market is valued at approximately US$9–11 billion in 2026. Local manufacturers supply over half of volume, while imported innovative products dominate value in oncology, immunology and rare disease. Currency dynamics and the SGK reference-pricing exchange rate materially affect dollar-denominated market size.
Who regulates pharmaceuticals in Turkey?
TİTCK (Türkiye İlaç ve Tıbbi Cihaz Kurumu — Turkish Medicines and Medical Devices Agency) regulates drug registration, GMP inspection, pricing and pharmacovigilance. Registration typically takes 12–18 months, and reimbursement requires a separate SGK application.
How does drug pricing work in Turkey?
Turkey uses external reference pricing benchmarked to the cheapest price among EU reference countries, converted at a government-fixed EUR/TRY exchange rate that is adjusted periodically. This fixed rate typically sits well below the market exchange rate, making Turkey one of the lowest-priced pharmaceutical markets in Europe.
Is local manufacturing required to sell pharmaceuticals in Turkey?
Local manufacturing is not legally required, but the localization policy links SGK reimbursement advantages to local production or technology transfer commitments. Many MNCs partner with Turkish manufacturers such as Abdi İbrahim or Gensenta for local production.
What are the biggest opportunities in Turkish pharma?
Oncology and specialty care (fastest value growth), biosimilars (policy-supported substitution), export manufacturing (EU-GMP capability at competitive cost), and OTC/consumer health. BioNixus supports market entry with TİTCK pathway intelligence, SGK payer research and physician fieldwork.
Data Sources & Methodology
This guide aggregates publicly available information from:
- TİTCK — Turkish Medicines and Medical Devices Agency
- SGK reimbursement communiqués
- İEİS (Turkish Pharmaceutical Manufacturers Association) publications
- Company filings and annual reports
- BioNixus proprietary research (Turkey & MENA, 2024–2026)
Company lists are editorial snapshots, not endorsements; market sizes are BioNixus estimate ranges synthesised from regulator and industry sources. For customised market intelligence on Turkey, contact our team.